Compare PEBO & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | DAWN |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 970.3M |
| IPO Year | N/A | 2021 |
| Metric | PEBO | DAWN |
|---|---|---|
| Price | $30.58 | $9.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $34.58 | $26.56 |
| AVG Volume (30 Days) | 175.2K | ★ 2.9M |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 5.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $555,347,000.00 | $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | $2.59 | $49.99 |
| P/E Ratio | $10.67 | ★ N/A |
| Revenue Growth | 10.92 | ★ 31.11 |
| 52 Week Low | $26.21 | $5.64 |
| 52 Week High | $33.83 | $13.53 |
| Indicator | PEBO | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 58.46 |
| Support Level | $31.43 | $8.13 |
| Resistance Level | $32.03 | $9.82 |
| Average True Range (ATR) | 0.50 | 0.59 |
| MACD | -0.11 | 0.10 |
| Stochastic Oscillator | 20.69 | 64.40 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.